(NASDAQ: CYTK) Cytokinetics's forecast annual revenue growth rate of 175.96% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.47%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.24%.
Cytokinetics's revenue in 2025 is $19,218,000.On average, 10 Wall Street analysts forecast CYTK's revenue for 2025 to be $1,513,621,511, with the lowest CYTK revenue forecast at $188,695,123, and the highest CYTK revenue forecast at $8,001,628,631. On average, 9 Wall Street analysts forecast CYTK's revenue for 2026 to be $21,543,489,384, with the lowest CYTK revenue forecast at $5,774,309,617, and the highest CYTK revenue forecast at $42,516,116,308.
In 2027, CYTK is forecast to generate $49,762,367,311 in revenue, with the lowest revenue forecast at $33,285,580,832 and the highest revenue forecast at $83,957,386,979.